Skip to main content

JAK Inhibitor Deal Benchmarks in Gastroenterology

Median Upfront
$565M
Range: $302M - $818M
Total Deal Value
$2.9B
Range: $1.8B - $3.9B
Royalty Rate
7.8% - 14.5%
Tiered up to 18.5%
Dev Milestones
$486M
Range: $318M - $656M
Model Your Deal

Market Analysis

JAK Inhibitor therapies in gastroenterology have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 jak inhibitor asset in gastroenterology is $565M, with total deal values reaching $2.9B. Development milestones average $486M, while regulatory milestones contribute $579M.

The gastroenterology jak inhibitor landscape is characterized by moderate-to-high competitive intensity concentrated in IBD and eosinophilic GI disorders. TL1A inhibitors, gut-selective integrins, and S1P modulators are broadening the therapeutic toolkit beyond TNF and integrin blockade. The recommended deal structure allocates approximately 20% to upfront payments and 80% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for jak inhibitor gastroenterology deals range from 7.8% to 14.5% at the base tier, with tiered escalation reaching 11.8%-18.5% on blockbuster sales. Commercial milestones averaging $1.3B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a jak inhibitor gastroenterology licensing deal?
Based on our analysis, Phase 2 jak inhibitor licensing deals in gastroenterology average $565M in upfront payments, with a range of $302M to $818M depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for jak inhibitor gastroenterology transactions?
The median total deal value for Phase 2 jak inhibitor assets in gastroenterology is $2.9B, ranging from $1.8B to $3.9B. This includes development milestones ($486M), regulatory milestones ($579M), and commercial milestones ($1.3B).
What royalty rates are standard for jak inhibitor deals in gastroenterology?
Base royalty rates for jak inhibitor gastroenterology transactions range from 7.8% to 14.5%, with tiered escalations reaching 11.8%-18.5% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in jak inhibitor gastroenterology deals?
JAK Inhibitor gastroenterology deals allocate approximately 80% of total deal value to milestones. Development milestones ($486M) make up the largest share, followed by commercial milestones ($1.3B) and regulatory milestones ($579M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Gastroenterology

View

Monoclonal Antibody in Gastroenterology

View

JAK Inhibitor in Immunology & Autoimmune

View

JAK Inhibitor in Dermatology

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included